• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Saturday, April 17, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Neuroscience

New treatment strategy could cut Parkinson’s disease off at the pass

Bioengineer by Bioengineer
September 30, 2016
in Neuroscience
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers at Johns Hopkins report they have identified a protein that enables a toxic natural aggregate to spread from cell to cell in a mammal’s brain — and a way to block that protein’s action. Their study in mice and cultured cells suggests that an immunotherapy already in clinical trials as a cancer therapy should also be tested as a way to slow the progress of Parkinson’s disease, the researchers say.

synuclein aggregates in the brain cells of mice with (top) and without (bottom) the LAG3 protein. Credit: Xiaobo Mao
synuclein aggregates in the brain cells of mice with (top) and without (bottom) the LAG3 protein.
Credit: Xiaobo Mao

A report on the study appears Sept. 30 in the journal Science.

Ted Dawson, M.D., Ph.D., director of the Institute for Cell Engineering at the Johns Hopkins University School of Medicine and one of the study’s leaders, says the new findings hinge on how aggregates of α-synuclein protein enter brain cells. Abnormal clumps of α-synuclein protein are often found in autopsies of people with Parkinson’s disease and are thought to cause the death of dopamine-producing brain cells.

A few years ago, Dawson says, a researcher at Goethe University in Germany published evidence for a novel theory that Parkinson’s disease progresses as α-synuclein aggregates spread from brain cell to brain cell, inducing previously normal α-synuclein protein to aggregate, and gradually move from the “lower” brain structures responsible for movement and basic functions to “higher” areas associated with processes like memory and reasoning. “There was a lot of skepticism, but then other labs showed α-synuclein might spread from cell to cell,” Dawson says. Intrigued, his research group began working with those of Valina Dawson, Ph.D., professor of neurology, and Han Seok Ko, Ph.D., assistant professor of neurology, to investigate how the aggregates enter cells.

The researchers knew they were looking for a certain kind of protein called a transmembrane receptor, which is found on the outside of a cell and works like a lock in a door, admitting only proteins with the right “key.” They first found a type of cells α-synuclein aggregates could not enter — a line of human brain cancer cells grown in the laboratory. The next step was to add genes for transmembrane receptors one by one to the cells and see whether any of them allowed the aggregates in. Three of the proteins did, and one, LAG3, had a heavy preference for latching on to α-synuclein aggregates over nonclumped α-synuclein.

The team next bred mice that lacked the gene for LAG3 and injected them with α-synuclein aggregates. “Typical mice develop Parkinson’s-like symptoms soon after they’re injected, and within six months, half of their dopamine-making neurons die,” Dawson says. “But mice without LAG3 were almost completely protected from these effects.” Antibodies that blocked LAG3 had similar protective effects in cultured neurons, the researchers found.

“We were excited to find not only how α-synuclein aggregates spread through the brain, but also that their progress could be blocked by existing antibodies,” says Xiaobo Mao, Ph.D., a research associate in Dawson’s laboratory and first author on the study.

Dawson notes that antibodies targeting LAG3 are already in clinical trials to test whether they can beef up the immune system during chemotherapy. If those trials demonstrate the drugs’ safety, the process of testing them as therapeutics for Parkinsons’ disease might be sped up, he says.

For now, the research team is planning to continue testing LAG3 antibodies in mice and to further explore LAG3’s function.

More than 1 million people in the United States live with Parkinson’s disease. The disease gradually strips away motor abilities, leaving people with a slow and awkward gait, rigid limbs, tremors, shuffling and a lack of balance. Its causes are not well-understood.

Web Source: Johns Hopkins Medicine.

Journal Reference:

Ted M. Dawson et al. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science, September 2016 DOI: 10.1126/science.aah3374

The post New treatment strategy could cut Parkinson’s disease off at the pass appeared first on Scienmag.

Share12Tweet7Share2ShareShareShare1

Related Posts

blank

Redox biomarker could predict progression of epilepsy

October 5, 2016
blank

Neural membrane’s structural instability may trigger multiple sclerosis

October 5, 2016

Scientists find new path in brain to ease depression

October 5, 2016

Key players responsible for learning and memory formation uncovered

October 3, 2016

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    Jonathan Wall receives $1.79 million to develop new amyloidosis treatment

    60 shares
    Share 24 Tweet 15
  • Terahertz accelerates beyond 5G towards 6G

    852 shares
    Share 341 Tweet 213
  • UofL, Medtronic to develop epidural stimulation algorithms for spinal cord injury

    56 shares
    Share 22 Tweet 14
  • A sturdier spike protein explains the faster spread of coronavirus variants

    44 shares
    Share 18 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

VirologyWeaponryUrbanizationViolence/CriminalsVehiclesZoology/Veterinary ScienceWeather/StormsVaccineUniversity of WashingtonUrogenital SystemVaccinesVirus

Recent Posts

  • USU researchers develop power converter for long-distance, underwater electric grids
  • The fate of the planet
  • The future of particle accelerators is here
  • Scientists may detect signs of extraterrestrial life in the next 5 to 10 years
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In